Targeting GPR40 receptor delays thymus aging in mice, early study shows

Researchers have demonstrated that activating the GPR40 receptor can delay age-related decline of the thymus in mice. The study utilized the compound GW9508 to target thymic epithelial cells, successfully increasing thymus weight and improving immune cell populations in 17-month-old female Black 6 mice.

The thymus is responsible for training T cells, but its functional tissue is gradually replaced by fat as the body ages, a process known as involution. In the experiment, the lowest dose of GW9508 yielded the most substantial results, producing an average thymus roughly 50 percent heavier than that of the control group.

Crucially, the treatment did not significantly affect the spleen and resulted in markedly lower creatinine levels across all treatment groups. Researchers interpret this as an indication of absent liver and kidney toxicity, alongside potential improvements in kidney function.

At a cellular level, the compound increased multiple subsets of thymocytes and specialized thymic epithelial cells. It also reduced cellular senescence dramatically; while a control group saw 85 percent of these cells become senescent after exposure to doxorubicin, the treatment group saw that figure drop to 20 percent.

The authors note significant limitations to the findings. The study was restricted to older female mice without a younger control group, involved no lifespan or pathogenic immune testing, and relied on sacrificing the animals for thymic examination.

For European healthcare systems and the biotech sector, the findings represent an early but notable step in the longevity economy. Thymic involution is a primary driver of age-related immune weakness, and finding a viable pharmacological intervention could eventually reduce the burden of infectious diseases in Europe’s rapidly aging demographic.

Because GW9508 has already been investigated for metabolic diseases, its repurposing could theoretically streamline the preclinical development pipeline for pharmaceutical companies. Investors will be watching closely to see if these murine results can be replicated in models that more closely mirror human immune aging.